A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer

ConclusionNab-paclitaxel may be a safe and effective later-line chemotherapeutic option for previously treated advanced NSCLC after standard of chemotherapies based on other trials.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionDifferentially expressed in tumors, PLA2G4A, PRKCB, PIK3R1, KDR, PLA2G1B and PTGS2 are potential therapeutic targets of Yupingfengsan in the treatment of LAD, and MAPK, VEGF and ErbB signaling pathways are involved.
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Publication date: Available online 21 August 2019Source: Seminars in Cancer BiologyAuthor(s): Btissame El Hassouni, Carlotta Granchi, Andrea Vallés-Martí, I Gede Putu Supadmanaba, Giulia Bononi, Tiziano Tuccinardi, Niccola Funel, Connie R. Jimenez, Godefridus J. Peters, Elisa Giovannetti, Filippo MinutoloAbstractCancer metastasis to distant organs is initiated by tumor cells that disseminate from primary heterogeneous tumors. The subsequent growth and survival of tumor metastases depend on different metabolic changes, which constitute one of the enigmatic properties of tumor cells. Aerobic glycolysis, ‘...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 August 2019Source: Seminars in Cancer BiologyAuthor(s): Yue Zhao, Jiahui Li, Dai Li, Zhefang Wang, Jiangang Zhao, Xiaolin Wu, Qiye Sun, Peter Ping Lin, Patrick Plum, Menglong Zhou, Zhen Zhang, Hans Schlösser, Peter J. Nelson, Christiane J. BrunsAbstractMore than 70% of gastrointestinal (GI) cancers are diagnosed with metastases, leading to poor prognosis. For some cancer patients with limited sites of metastatic tumors, the term oligometastatic disease (OMD) has been coined as opposed to systemic polymetastasis (PMD) disease. Stephan Paget first described an organ-specific pattern...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 August 2019Source: Seminars in Cancer BiologyAuthor(s): Francesco Spagnolo, Andrea Boutros, Enrica Tanda, Paola QueiroloAbstractThe past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 August 2019Source: Seminars in Cancer BiologyAuthor(s): Carlos S. MorenoAbstractSOX4 is an essential developmental transcription factor that regulates stemness, differentiation, progenitor development, and multiple developmental pathways including PI3K, Wnt, and TGFβ signaling. The SOX4 gene is frequently amplified and overexpressed in over 20 types of malignancies, and multiple lines of evidence support that notion that SOX4 is an oncogene. Its overexpression is due to both gene amplification and to activation of PI3K, Wnt, and TGFβ pathways that SOX4 regulates. SOX4 interac...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Conclusion Nab-paclitaxel plus carboplatin, without dose reduction, is indicated to be toxic and intolerable as first-line chemotherapy in elderly Japanese patients with advanced NSCLC. Care must be taken when extrapolating the results of a clinical trial into clinical practice, particularly when the resulting subgroup analysis is of elderly patients because this patient group is composed of a heterogeneous population. Clinical trial registration UMIN-CTR identifier: UMIN000010738.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Conclusions: The combination was well tolerated, the RP2D is 36mg/m2 ADI-PEG 20 weekly with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 every 3 weeks. Robust clinical activity has been observed with 78% pt having PR as best response on CT scan, as well as PR and SD in2 pt with sarcomatoid mesothelioma. The tolerability and response / disease control rate suggest that this combination may have clinical utility as first line treatment for these malignancies in ASS1-deficient pt. RP2D expansion cohorts are ongoing for pt with pleural mesothelioma or non-squamous NSCLC.Citation Format: Simon Pacey, James F. Spicer, Pui Ying Ch...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Clinical Trials: Poster Presentations - Proffered Abstracts Source Type: research
This article summarizes pharmacological, efficacy and tolerability data relevant to the use of nab-paclitaxel in this indication. Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. The nab-paclitaxel regimen also provided benefit over the sb-paclitaxel regimen in certain patient subgroups, including patients with squamous cell histology (in terms of ORR) and patients who ...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
ConclusionThe nab‐paclitaxel chemotherapy could achieve significant tumour responses and encourage survival in advanced NSCLC patients with tolerable toxicities. Further clinical studies are needed to explore the optimal therapy regimen and target users.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLE Source Type: research
CONCLUSIONS: In people over the age of 70 with advanced NSCLC who do not have significant co-morbidities, increased survival with platinum combination therapy needs to be balanced against higher risk of major adverse events when compared with non-platinum therapy. For people who are not suitable candidates for platinum treatment, we have found low-quality evidence suggesting that non-platinum combination and single-agent therapy regimens have similar effects on survival. We are uncertain as to the comparability of their adverse event profiles. Additional evidence on quality of life gathered from additional studies is neede...
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Tags: Cochrane Database Syst Rev Source Type: research
More News: Abraxane | Anemia | Brain | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Hematology | Lung Cancer | Nanotechnology | Neurology | Non-Small Cell Lung Cancer | Peripheral Neuropathy | Study